Search
for

    Sort by

    Research 961–990 of 1000+

    1. 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials Journal of the American Academy of Dermatology · 2022 · 3 citations
    2. Grading of hirsutism: a practical approach to the modified Ferriman-Gallwey scoring system Postepy Dermatologii I Alergologii · 2021 · 3 citations
    3. LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1) Journal of Investigative Dermatology · 2021 · 3 citations
    4. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial Journal of the American Academy of Dermatology · 2025 · 2 citations
    5. Duration of current alopecia areata episode predicts the effectiveness of baricitinib in Japanese patients with alopecia areata: a single-center retrospective study Journal of Dermatological Treatment · 2025 · 2 citations
    6. Efficacy of Upadacitinib in Treating Alopecia Areata, Atopic Dermatitis, and Th1 Comorbidities in Pediatric Patients: A Comprehensive Case Series and Literature Review Journal of Clinical Medicine · 2025 · 2 citations
    7. Switching JAK inhibitors: evaluating baricitinib’s effectiveness in alopecia areata after tofacitinib failure Archives of Dermatological Research · 2025 · 2 citations
    8. Serum interleukin-37 and its gene polymorphism (rs3811047) in Egyptian patients with alopecia areata Gene Reports · 2024 · 2 citations
    9. 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials Journal of the American Academy of Dermatology · 2024 · 2 citations
    10. 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial Journal of the American Academy of Dermatology · 2023 · 2 citations
    11. The Relationship Between ABO And Rh Blood Groups With Alopecia Areata Dermatology Practical & Conceptual · 2023 · 2 citations
    12. A study on histopathological and dermoscopic correlations in pityriasis versicolor IP Indian journal of clinical and experimental dermatology · 2022 · 2 citations
    13. Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population Dermatologic Therapy · 2022 · 2 citations
    14. Not just thinning: A case of alopecia universalis after mild COVID-19 JAAD Case Reports · 2022 · 2 citations
    15. Correlation between serum granulysin level and clinical activity in patients with alopecia areata before and after tofacitinib therapy Journal of Cosmetic Dermatology · 2020 · 2 citations
    16. Cellular retinol‐binding protein‐1 expression increases with increasing clinical severity of alopecia areata Journal of cosmetic dermatology · 2018 · 2 citations
    17. A clinical study on alopecia areata International journal of research in dermatology · 2018 · 2 citations
    18. Etiopathogenesis of Alopecia Areata Hair therapy & transplantation · 2014 · 2 citations
    19. Criticising Modified Ferriman-Gallwey Scroring System in the Evaluation of Hirsutism in 1034 Turkish Women Türkiye klinikleri tıp bilimleri dergisi · 2013 · 2 citations
    20. Finasteride: Middle-Age Cure-All for Alopecia and Benign Prostatic Hyperplasia?–Reply–I Mayo Clinic Proceedings · 2006 · 2 citations
    21. Microsporum gypseum isolated from a feline case of dermatophytosis Mycoses · 2001 · 2 citations
    22. Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition Journal of Dermatological Treatment · 2026 · 1 citations
    23. Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study American Journal of Clinical Dermatology · 2026 · 1 citations
    24. Effectiveness and safety of Baricitinib in alopecia areata: a prospective cohort study Journal of Dermatological Treatment · 2025 · 1 citations
    25. Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study SKIN The Journal of Cutaneous Medicine · 2025 · 1 citations
    26. Dermoscopic Analysis of Patients with and without Poor Prognostic Indicators in Alopecia Areata – A Comparative Study Indian Dermatology Online Journal · 2025 · 1 citations
    27. Complete responses and SALT zero scores in alopecia areata: not the same Journal of Dermatological Treatment · 2024 · 1 citations
    28. 723 - Efficacy of ritlecitinib in patients with alopecia areata by extent of hair loss at baseline: post hoc analysis of the phase 3 long-term ALLEGRO-LT study British Journal of Dermatology · 2024 · 1 citations
    29. A new era for alopecia areata: New treatments and improved knowledge of the condition 2024 · 1 citations
    30. Systemic Tofacitinib in Alopecia Areata: A Single Center Retrospective Descriptive Cohort Study Arab Board Medical Journal · 2024 · 1 citations